These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Synthesis and biological activity of novel, potent and long-acting analogs of AC-CCK-7 with high affinity for peripheral (type A) receptors. Danho W; Makofske RC; Swistok J; Michalewsky J; Gabriel T; Marks N; Berg MJ; Baird L; Geiler V; Mackie G Pept Res; 1991; 4(2):59-65. PubMed ID: 1815779 [TBL] [Abstract][Full Text] [Related]
43. Role of N- and C-terminal substituents on the CCK-B agonist-antagonist pharmacological profile of Boc-Trp-Phg-Asp-Nal-NH2 derivatives. Weng JH; Blommaert AG; Moizo L; Bado A; Ducos B; Böhme A; Garbay C; Roques BP Bioorg Med Chem; 1996 Apr; 4(4):563-73. PubMed ID: 8735845 [TBL] [Abstract][Full Text] [Related]
44. Products of cholecystokinin (CCK)-octapeptide proteolysis interact with central CCK receptors. Steardo L; Knight M; Tamminga CA; Chase TN Neurosci Lett; 1985 Mar; 54(2-3):319-25. PubMed ID: 2986058 [TBL] [Abstract][Full Text] [Related]
45. Partial agonism by gastrin for a cholecystokinin receptor mediating pepsinogen secretion. Tang LH; Miller MD; Goldenring JR; Modlin IM; Hersey SJ Am J Physiol; 1993 Nov; 265(5 Pt 1):G865-72. PubMed ID: 8238515 [TBL] [Abstract][Full Text] [Related]
47. Solid phase synthesis of a fully active analogue of cholecystokinin using the acid-stable Boc-Phe (p-CH2) SO3H as a substitute for Boc-Tyr(SO3H) in CCK8. Gonzalez-Muniz R; Cornille F; Bergeron F; Ficheux D; Pothier J; Durieux C; Roques BP Int J Pept Protein Res; 1991 Apr; 37(4):331-40. PubMed ID: 1894448 [TBL] [Abstract][Full Text] [Related]
48. Full agonists of CCK8 containing a nonhydrolyzable sulfated tyrosine residue. Marseigne I; Roy P; Dor A; Durieux C; Pélaprat D; Reibaud M; Blanchard JC; Roques BP J Med Chem; 1989 Feb; 32(2):445-9. PubMed ID: 2464062 [TBL] [Abstract][Full Text] [Related]
49. Stimulation of delta-opioid receptors reduces the in vivo binding of the cholecystokinin (CCK)-B-selective agonist [3H]pBC 264: evidence for a physiological regulation of CCKergic systems by endogenous enkephalins. Ruiz-Gayo M; Durieux C; Fournié-Zaluski MC; Roques BP J Neurochem; 1992 Nov; 59(5):1805-11. PubMed ID: 1357099 [TBL] [Abstract][Full Text] [Related]
50. Neostriatal neurons of rats can be influenced by cholecystokinin-A receptor agonists. Davidowa H; Wetzel K; Henklein P Neuropeptides; 1997 Jun; 31(3):231-5. PubMed ID: 9243519 [TBL] [Abstract][Full Text] [Related]
51. Preclinical and initial clinical evaluation of 111In-labeled nonsulfated CCK8 analog: a peptide for CCK-B receptor-targeted scintigraphy and radionuclide therapy. de Jong M; Bakker WH; Bernard BF; Valkema R; Kwekkeboom DJ; Reubi JC; Srinivasan A; Schmidt M; Krenning EP J Nucl Med; 1999 Dec; 40(12):2081-7. PubMed ID: 10616889 [TBL] [Abstract][Full Text] [Related]
52. Synthesis of human CCK26-33 and CCK-33 related analogues on 2,4-DMBHA and TMBHA. Miranda MT; Liddle RA; Rivier JE J Med Chem; 1993 Jun; 36(12):1681-8. PubMed ID: 7685390 [TBL] [Abstract][Full Text] [Related]
54. Conformational behavior of cyclic CCK-related peptides determined by 400-MHz 1H-NMR: relationships with affinity and selectivity for brain receptors. Roy P; Charpentier B; Durieux C; Dor A; Roques BP Biopolymers; 1989 Jan; 28(1):69-79. PubMed ID: 2720122 [TBL] [Abstract][Full Text] [Related]
55. Conformational analysis of CCK-B agonists using 1H-NMR and restrained molecular dynamics: comparison of biologically active Boc-Trp-(N-Me) Nle-Asp-Phe-NH2 and inactive Boc-Trp-(N-Me)Phe-Asp-Phe-NH2. Goudreau N; Weng JH; Roques BP Biopolymers; 1994 Feb; 34(2):155-69. PubMed ID: 8142585 [TBL] [Abstract][Full Text] [Related]
56. Analogs of Ac-CCK-7 incorporating dipeptide mimics in place of Met28-Gly29. Tilley JW; Danho W; Shiuey SJ; Kulesha I; Swistok J; Makofske R; Michalewsky J; Triscari J; Nelson D; Weatherford S J Med Chem; 1992 Oct; 35(21):3774-83. PubMed ID: 1433191 [TBL] [Abstract][Full Text] [Related]
57. Structure-activity relationship studies on cholecystokinin: analogues with partial agonist activity. Galas MC; Lignon MF; Rodriguez M; Mendre C; Fulcrand P; Laur J; Martinez J Am J Physiol; 1988 Feb; 254(2 Pt 1):G176-82. PubMed ID: 2450468 [TBL] [Abstract][Full Text] [Related]
58. Replacement of glycine with dicarbonyl and related moieties in analogues of the C-terminal pentapeptide of cholecystokinin: CCK(2) agonists displaying a novel binding mode. Bellier B; Million ME; DaNascimento S; Meudal H; Kellou S; Maigret B; Garbay C J Med Chem; 2000 Oct; 43(20):3614-23. PubMed ID: 11020275 [TBL] [Abstract][Full Text] [Related]
59. Development of CCK-B antagonists. Horwell DC Neuropeptides; 1991 Jul; 19 Suppl():57-64. PubMed ID: 1881533 [TBL] [Abstract][Full Text] [Related]
60. Synthesis and biological activity of some partially modified retro-inverso analogues of cholecystokinin. Rodriguez M; Galas MC; Lignon MF; Mendre C; Laur J; Aumelas A; Martinez J J Med Chem; 1989 Oct; 32(10):2331-9. PubMed ID: 2477546 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]